Drug Profile

HSK 39004

Alternative Names: HSK-39004

Latest Information Update: 14 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Haisco Pharmaceutical Group
Class Antiasthmatics
Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

13 Aug 2025 Phase-II clinical trials in Asthma (Inhalation) prior to August 2025 (Haisco Pharmaceutical pipeline, August 2025).
07 Aug 2025 Haisco Pharmaceutical plans a phase II trial for Chronic obstructive pulmonary disease in China (Inhalation) (NCT07108699) .
06 May 2025 Haisco Pharmaceutical completes a phase I trial in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation, Powder) (NCT06971198)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com